Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3226-3232

  Csajka, Chantal ^a   Marzolini, Catia ^a   Fattinger, Karin ^b   Décosterd, Laurent A ^a   Telenti, Amalio ^a   Biollaz, Jérôme ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; RITONAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; BAYES THEOREM; BODY WEIGHT; COLIC; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; NEPHROLITHIASIS; NEPHROSIS; PAIN; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BAYES THEOREM; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POPULATION;

EID: 4344588324     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3226-3232.2004     Document Type: Article

References (29)

1. Aarnoutse, R. E., K. J. T. Grintjes, D. S. C. Telgt, M. Stek, P. W. H. Hugen, P. Reiss, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2002. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 71:57-67.
2. Acosta, E. P., J. G. Gerber, and the Adult Pharmacology Committee of the AIDS Clinical Trials Group. 2002. Position paper on therapeutic drug monitoring of the antiretroviral agents. AIDS Res. Hum. Retrovir. 18:825-834.
3. Acosta, E. P., K. Henry, L. Baken, L. M. Page, and C. V. Fletcher. 1999. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
4. Anderson, P. L., R. C. Brundage, T. N. Kakuda, and C. V. Fletcher. 2002. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin. Pharmacol. Ther. 71:280-285.
5. Bates, D. M., and D. G. Watts. 1988. Nonlinear regression analysis and its applications. J. Wiley and Sons, New York, N.Y.
6. Boubaker, K., P. Sudre, F. Bally, G. Vogel, J. Y. Meuwly, M. P. Glauser, and A. Telenti. 1998. Changes in renal function associated with indinavir. AIDS 12:249-254.
7. Burger, D., M. Boyd, C. Duncombe, M. Felderhof, A. Mahanontharit, K. Ruxrungtham, S. Ubolyam, M. Stek, D. Cooper, J. Lange, P. Phanupak, and P. Reiss. 2003. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J. Antimicrob. Chemother. 51:1231-1238.
8. Burger, D., P. Hugen, P. Reiss, I. Gyssens, M. Schneider, F. Kroon, G. Schreij, K. Brinkman, C. Richter, J. Prins, R. Aarnoutse, and J. Lange for the ATHENA Cohort Study Group. 2003. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 17:1157-1165.
9. Burger, D. M., M. C. Siebers, P. W. H. Hugen, R. E. Aarnoutse, Y. A. Hekster, and P. P. Koopmans. 2002. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J. Acquir. Immune Defic. Syndr. 29:101-102.
10. Burger, D. M., P. W. H. Hugen, R. E. Aarnoutse, J. P. Dieleman, J. M. Prins, T. van der Pol, J. H. ten Veen, J. W. Mulder, P. L. Meenhorst, W. L. Blok, J. T. van der Meer, P. Reiss, and J. M. A. Lange. 2001. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety and efficacy. J. Acquir. Immune Defic. Syndr. 26:218-224.
11. Carver, P. L., D. Fleisher, S. Y. Zhou, D. Kaul, P. Kazanjian, and C. Li. 1999. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm. Res. 16:718-724.
12. D'Arminio Monforte, A., A. C. Lepri, G. Rezza, P. Pezzotti, A. Antinori, A. N. Phillips, G. Angarano, V. Colangeli, A. De Luca, G. Ippolito, L. Caggese, F. Soscia, G. Filice, F. Gritti, P. Narciso, U. Tirelli, M. Moroni, et al. 2000. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 14:499-507.
13. DiCenzo, R., A. Forrest, K. E. Squires, S. M. Hammer, M. A. Fischl, H. Wu, R. Cha, G. D. Morse, and the Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. 2003. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1929-1935.
14. Dielman, J. P., I. C. Gyssens, M. E. Van der Ende, S. De Marie, and D. M. Burger. 1999. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13:473-478.
15. Durant, J., P. Cleenbergh, R. Garraffo, P. Halfon, S. Icard, P. Del Guidice, N. Montagne, J. M. Shapiro, and P. Dellamonica. 2000. Importance of protease inhibitor plasma level in patients treated with genotypic-guided therapy: pharmacological data from the VIRADAPT study. AIDS 14:1333-1339.
16. Fletcher, C. V., P. L. Anderson, T. N. Kakuda, T. W. Schacker, K. Henry, C. R. Gross, and R. C. Brundage. 2002. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16:551-560.
17. Fletcher, C. V. 1999. Pharmacologic considerations for therapeutic success with antiretroviral agents. Ann. Pharmacother. 33:989-995.
18. Ghosn, J., C. Lamotte, H. Ait-Mohand, M. Wirden, R. Agher, L. Schneider, F. Bricaire, C. Duvivier, V. Calvez, G. Peytavin, and C. Katlama. 2003. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 17:209-214.
19. Kakuda, T. N., L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher. 2001. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45:236-242.
20. Lee, C., and M. M. Gottesman. 1998. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Investig. 101:287-288.
21. Letendre, S. L., E. V. Capparelli, R. J. Ellis, J. A. McCutchan, and the HIV Neurobehavioral Research Center Group. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 44:2173-2175.
22. Lin, J. H., M. Chiba, I. W. Chen, J. A. Nishime, and K. J. Vastag. 1996. Sex-dependent pharmacokinetics of indinavir. Drug Metab. Dispos. 24:1298-1306.
23. Marzolini, C., A. Telenti, T. Buclin, J. Biollaz, and L. A. Decosterd. 2000. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the nonnucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J. Chromatogr. B Biomed. Sci. Appl. 740:43-58.
24. Pfister, M., L. Labbé, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, L. B. Sheiner, and the AIDS Clinical Trial Group Protocol 398 Investigators. 2003. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS clinical trial group study 398. Antimicrob. Agents Chemother. 47:130-137.
25. Rayner, C. R., K. J. Galbraith, J. L. Marriott, and G. J. Duncan. 2002. A critical evaluation of the therapeutic range of indinavir. Ann. Pharmacother. 36:1230-1237.
26. Sheiner, L. B., S. Beal, B. Rosenberg, and V. V. Marathe. 1979. Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther. 26:294-305.
27. Shulman, N., A. Zolopa, D. Havlir, A. Hsu, C. Renz, S. Boller, P. Jiang, R. Rode, J. Gallant, E. Race, D. J. Kempf, and E. Sun. 2002. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46:3907-3916.
28. Van Heeswijk, R. P. G., A. I. Veldkamp, R. M. W. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. Lange, J. H. Beijnen, and P. L. Meenhorst. 1999. The steady-state plasma pharmacokinetics of indinavir alone or in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 13:95-99.
29. Zhou, X. J., D. Havlir, D. Richman, E. P. Acosta, M. Hirsch, A. C. Collier, P. Tebas, J. P. Sommadossi, and the AIDS Clinical Trials Study 343 Investigators. 2000. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 14:2869-2876.